Nonalcoholic fatty liver disease and atrial fibrillation: the main markers of this association
DOI:
https://doi.org/10.14739/2310-1210.2023.3.273664Keywords:
atrial fibrillation, non-alcoholic fatty liver disease, fibrosis, periostinAbstract
The prevalence of nonalcoholic fatty liver disease (NAFLD) and atrial fibrillation (AF) has increased globally in recent years. According to recent studies, NAFLD and AF affect approximately 32 % and 0.51 % of the general population, respectively.
Aim. To examine the association between NAFLD and AF by using the FibroTest-4 (FIB-4) and the NAFLD Fibrosis score (NFS) and measuring periostin levels.
Materials and methods. In this study, we enrolled 96 patients diagnosed with NAFLD and divided them in two groups, the main group – 35 patients with NAFLD + AF and the control group – 61 patients with NAFLD alone. NFS and FIB-4 indices were calculated and serum periostin level was measured.
Results. The NAFLD + AF group had higher levels of periostin (10.80 ± 1.60 ng/ml vs. 9.80 ± 1.75 ng/ml, p < 0.001) and higher NFS (-1.05 ± 1.46 vs. -2.65 ± 1.63, p < 0.001) and FIB-4 scores (1.34 ± 0.86 vs 1.07 ± 0.60, p = 0.048). Periostin has been found to be associated with the risk of NAFLD + AF with an OR of 2.079 (95 % CI: 1.418–3.048, p < 0.001). Similar results were with NFS (OR = 3.233, 95 % CI: 1.970–5.303, p < 0.001) and FIB-4 (OR = 2.498, 95 % CI: 1.109–5.627, p = 0.027). The receiver operating characteristic (ROC) analysis was performed using three variables, NFS, FIB-4 and periostin, to determine their ability to distinguish between patients with NAFLD + AF and NAFLD alone. The results have shown that the NFS had the highest area under the curve (AUC) with a value of 0.868 (95 % CI: 0.792–0.943, p < 0.001), indicating excellent discriminatory ability. FIB-4 had an AUC of 0.651 (95 % CI: 0.537–0.765, p = 0.014), while periostin had an AUC of 0.759 (95 % CI: 0.660–0.858, p < 0.001).
Conclusions. These findings have suggested a strong association between NAFLD and AF and highlighted the importance of considering AF as a potential complication in patients with NAFLD. Both the use of the FIB-4 and NFS indices and measurement of periostin levels have been proved to be effective in detecting this association.
References
Pouwels, S., Sakran, N., Graham, Y., Leal, A., Pintar, T., Yang, W., Kassir, R., Singhal, R., Mahawar, K., & Ramnarain, D. (2022). Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC endocrine disorders, 22(1), 63. https://doi.org/10.1186/s12902-022-00980-1
Ahmad, M. I., Khan, M. U., Kodali, S., Shetty, A., Bell, S. M., & Victor, D. (2022). Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges. Journal of Hepatocellular Carcinoma, 9, 477-496. https://doi.org/10.2147/JHC.S344559
Brundel, B. J. J. M., Ai, X., Hills, M. T., Kuipers, M. F., Lip, G. Y. H., & Groot, N. M. S. de. (2016). Atrial fibrillation. Nature Reviews. Disease Primers, 2(1), 16017. https://doi.org/10.1038/NRDP.2016.17
Riazi, K., Azhari, H., Charette, J. H., Underwood, F. E., King, J. A., Afshar, E. E., Swain, M. G., Congly, S. E., Kaplan, G. G., & Shaheen, A. A. (2022). The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. The Lancet. Gastroenterology & Hepatology, 7(9), 851-861. https://doi.org/10.1016/S2468-1253(22)00165-0
Lippi, G., Sanchis-Gomar, F., & Cervellin, G. (2021). Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. International Journal of Stroke , 16(2), 217-221. https://doi.org/10.1177/1747493019897870
Ismaiel, A., & Dumitraşcu, D. L. (2019). Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis-Literature Review. Frontiers in Medicine, 6, 202. https://doi.org/10.3389/FMED.2019.00202
Gong, H., Liu, X., & Cheng, F. (2021). Relationship between non-alcoholic fatty liver disease and cardiac arrhythmia: a systematic review and meta-analysis. The Journal of International Medical Research, 49(9), 3000605211047074. https://doi.org/10.1177/03000605211047074
Jia, Y., Zhong, F., Jiang, S., Guo, Q., Jin, H., Wang, F., Li, M., Wang, L., Chen, A., Zhang, F., Shao, J., & Zheng, S. (2019). Periostin in chronic liver diseases: Current research and future perspectives. Life Sciences, 226, 91-97. https://doi.org/10.1016/J.LFS.2019.04.021
Marchesini, G., Day, C. P., Dufour, J. F., Canbay, A., Nobili, V., Ratziu, V., Tilg, H., Roden, M., Gastaldelli, A., Yki-Järvinen, H., Schick, F., Vettor, R., Frühbeck, G., & Mathus-Vliegen, L. (2016). EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Obesity Facts, 9(2), 65. https://doi.org/10.1159/000443344
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström-Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P. E., Fauchier, L., Filippatos, G., Kalman, J. M., la Meir, M., Lane, D. A., Lebeau, J.-P., Lettino, M., Lip, G. Y. H., Pinto, F. J., … Zakirov, N. U. (2021). 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 42(5), 373-498. https://doi.org/10.1093/eurheartj/ehaa612
Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., Sulkowski, M. S., Torriani, F. J., Dieterich, D. T., Thomas, D. L., Messinger, D., & Nelson, M. (2006). Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (Baltimore, Md.), 43(6), 1317-1325. https://doi.org/10.1002/HEP.21178
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., Lindor, K., Sanderson, S. O., Lenzi, M., Adams, L. A., Kench, J., Therneau, T. M., & Day, C. P. (2007). The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology (Baltimore, Md.), 45(4), 846-854. https://doi.org/10.1002/HEP.21496
Cai, X., Zheng, S., Liu, Y., Zhang, Y., Lu, J., & Huang, Y. (2020). Nonalcoholic fatty liver disease is associated with increased risk of atrial fibrillation. Liver International , 40(7), 1594-1600. https://doi.org/10.1111/LIV.14461
Kang, M. K., Park, J. G., & Kim, M. C. (2020). Association between Atrial Fibrillation and Advanced Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. Yonsei Medical Journal, 61(10), 860. https://doi.org/10.3349/YMJ.2020.61.10.860
Mózes, F. E., Lee, J. A., Selvaraj, E. A., Jayaswal, A. N. A., Trauner, M., Boursier, J., Fournier, C., Staufer, K., Stauber, R. E., Bugianesi, E., Younes, R., Gaia, S., Lupșor-Platon, M., Petta, S., Shima, T., Okanoue, T., Mahadeva, S., Chan, W. K., Eddowes, P. J., … Doward, L. (2022). Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut, 71(5), 1006-1019. https://doi.org/10.1136/GUTJNL-2021-324243
Wang, Z., Wang, Y., Luo, F., Zhai, Y., Li, J., Chen, Y., Li, Q., Zhu, L., Jiao, S., Liu, P., Zhou, Y., Chen, Y., Dong, J., & Sun, Y. (2022). Impact of advanced liver fibrosis on atrial fibrillation recurrence after ablation in non-alcoholic fatty liver disease patients. Frontiers in Cardiovascular Medicine, 9, 960259. https://doi.org/10.3389/fcvm.2022.960259
Zhu, J. Z., Zhu, H. T., Dai, Y. N., Li, C. X., Fang, Z. Y., Zhao, D. J., Wan, X. Y., Wang, Y. M., Wang, F., Yu, C. H., & Li, Y. M. (2016). Serum periostin is a potential biomarker for non-alcoholic fatty liver disease: a case-control study. Endocrine, 51(1), 91-100. https://doi.org/10.1007/S12020-015-0735-2
Fang, L., Jin, H., Li, M., Cheng, S., & Liu, N. (2022). Serum periostin as a predictor of early recurrence of atrial fibrillation after catheter ablation. Heart and Vessels, 37(12), 2059-2066. https://doi.org/10.1007/S00380-022-02115-X/METRICS
Smirne, C., Mulas, V., Barbaglia, M. N., Mallela, V. R., Minisini, R., Barizzone, N., Burlone, M. E., Pirisi, M., & Grossini, E. (2020). Periostin Circulating Levels and Genetic Variants in Patients with Non-Alcoholic Fatty Liver Disease. Diagnostics, 10(12), 1003. https://doi.org/10.3390/diagnostics10121003
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
